key: cord-0810552-4as3mu9d
authors: Zang, Jinkai; Zhang, Chao; Yin, Yannan; Xu, Shiqi; Qiao, Weihua; Lavillette, Dimitri; Wang, Haikun; Huang, Zhong
title: An mRNA vaccine candidate for the SARS-CoV-2 Omicron variant
date: 2022-02-07
journal: bioRxiv
DOI: 10.1101/2022.02.07.479348
sha: 3709d0c9ce443189f6410810752b082b2597bec0
doc_id: 810552
cord_uid: 4as3mu9d

The newly emerged Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains more than 30 mutations on the spike protein, 15 of which are located within the receptor binding domain (RBD). Consequently, Omicron is able to extensively escape existing neutralizing antibodies and may therefore compromise the efficacy of current vaccines based on the original strain, highlighting the importance and urgency of developing effective vaccines against Omicron. Here we report the rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron. This mRNA vaccine encodes the RBD of Omicron (designated RBD-O) and is formulated with lipid nanoparticle. Two doses of the RBD-O mRNA vaccine efficiently induce neutralizing antibodies in mice; however, the antisera are effective only on the Omicron variant but not on the wildtype and Delta strains, indicating a narrow neutralization spectrum. It is noted that the neutralization profile of the RBD-O mRNA vaccine is opposite to that observed for the mRNA vaccine expressing the wildtype RBD (RBD-WT). Our work demonstrates the feasibility and potency of an RBD-based mRNA vaccine specific to Omicron, providing important information for further development of bivalent or multivalent SARS-CoV-2 vaccines with broad-spectrum efficacy.

In this study, we adopted a non-replicating mRNA vaccine platform to rapidly 

Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to 163 current COVID-19 vaccines

Heavily mutated Omicron variant puts scientists on alert

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from 167 neutralizing antibody responses

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have 171 reduced neutralizing activity against Beta and Omicron pseudoviruses

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion 176 and viral entrance

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Overlay, merge of the blue (DAPI) and green 192 (RBD) channels. Scale bars = 20 μm. (C) The culture supernatants of 193 mRNA-transfected HEK293T cells were analyzed for RBD expression by western 194 blotting with HRP-conjugated anti-His tag antibody and anti-RBD

RBD-O mRNA 197 (n = 8), or luciferase-mRNA (Ctrl; n = 5) vaccines at weeks 0 and 2. Serum samples 198 were collected from individual mice at weeks 2 and 4. (E) The week-2 and week-4 199 antisera were diluted 1:100 and analyzed for RBD-WT-binding activity by ELISA

Neutralizing titers of the week-4 antisera samples from each group against WT

Serum samples that exhibited less than 50% 202 neutralization at the lowest serum dilution (1:200) were assigned a NT50 value of 100 203 for statistical analysis. Each symbol represents one mouse. (G) Neutralizing titers of 204 the week-4 antisera from RBD-WT mRNA group (left panel) and RBD-O mRNA group 205 (right panel) against SARS-CoV-2 PV. The geometric mean of NT50 values was 206 shown. For panels E-F, data are presented as mean ± SEM